ArticleMedicine2025
Comprehensive investigation of a new signature integrating lipid metabolism and immune-related genes for clear cell renal cell carcinoma prognosis and immunometabolism landscapes.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-omics studies have significantly advanced our understanding of ccRCC. These studies have revealed that aggressive ccRCC is closely associated with metabolic reprogramming, particularly involving lipid metabolism. Recent studies have highlighted the crosstalk between lipid metabolism and immune function in the tumor microenvironment (TME) of ccRCC. However, prognostic models integrating both pathways remain underdeveloped. A detailed analysis was conducted on the varied lipid metabolism subtypes utilizing 638 records of clear cell renal cell carcinoma from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, focusing on lipid metabolism genes and immune-related genes (LRGs). The clinical importance, functional status, TME interaction, and genetic alterations of various subtypes were further investigated. A novel grading system, the lipid-immune score (LIS), was created and validated. Two distinct subgroups, characterized by elevated expression of lipid metabolism genes and exhibiting traits of tumor metabolism and proliferation, are classified as lipid metabolism phenotypes. The lipid metabolism phenotype exhibits a more favorable prognosis, enhanced anti-tumor immunity, and increased sensitivity to immunotherapy. The expression of more LRGs, the enrichment of immunoreactive pathways, and the infiltration of effector immune cells are characterized as immunoreactive phenotypes. The prognosis for the immunoactive phenotype is unfavorable and is more prevalent in patients experiencing tumor progression. Furthermore, BAP1 is a pivotal mutant gene in the immunoactive subtype. LIS was ultimately shown as a reliable predictor of overall survival (OS) and immunotherapy outcomes in patients with clear cell renal cell carcinoma. We systematically analyzed immune- and lipid metabolism-related genes, identifying 2 distinct molecular subtypes with differing biological functions, immune profiles, and clinical outcomes. We also developed a LIS that effectively predicts patient prognosis and immunotherapy response, offering a new strategy for precision medicine in ccRCC. Our research elucidates the relationship between lipid metabolism and immune response, offering a distinctive strategy for therapeutic management and precision medicine in patients with clear cell renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.